Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

Incyte Corp.

INCYNASDAQEQUITYCurrent

SEC Filing

Filed Sep 17, 2026Accepted Sep 17, 2026, 4:04 PM EDTCIK 879169Accession 0001205703-26-000030
Share

Company context

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Investor. Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Current securities

Recent company filings

  1. 144 filingSep 15, 2026
  2. 8-K filingAug 31, 2026
  3. 4 filingAug 27, 2026
  4. 144 filingAug 19, 2026
  5. 144 filingAug 12, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗